SPECIAL REPORT: Understanding Treatment Dynamics and Needs in Juvenile Idiopathic Arthritis

Title	Published	Price
Prostate Cancer Drug Discoveries: What the Future Holds By: Espicom Healthcare Intelligence Prostate cancer is the second leading cause of cancer in the US and the third most common cancer worldwide. More than two million men in the US suffer with prostate cancer. Find out more about \| more... Search inside this report	11/5/2009	$2,460.00
BI for Drug Development: Oracle Introduces Clinical Development Analytics By: IDC This IDC Health Insights Perspective highlights the announcement of a dedicated life science business intelligence (BI) solution introduced recently at Oracle OpenWorld 2009 that promises to deliver actionable insights into clinical development processes. Oracle Clinical \| more... Search inside this report	11/1/2009	$1,500.00
Biotechnology (Pharmaceuticals) Report By: Plimsoll Publishing Ltd. The Global Biotechnology Report Plimsoll Publishing Ltd. Do you know.... The top 7 best trading partners in the industry? Which company has the highest sales growth? Which companies have the highest levels of debt? This report is an in-depth financial evaluation \| more...	11/1/2009	$1,500.00
Biopharmaceuticals Industry Report By: Plimsoll Publishing Ltd. The Global Biopharmaceuticals Industry Report Plimsoll Publishing Ltd. Do you know.... The top 7 best trading partners in the industry? Which company has the highest sales growth? Which companies have the highest levels of debt? This report is an in-depth financial \| more...	11/1/2009	$1,500.00
Freedonia Focus on Biologicals By: Freedonia Focus This report discusses US biologicals demand for the years 2003 and 2008, with forecasts for 2013. Topics covered include market size, product and market segmentation, technological and product development, regulatory considerations, market environment, \| more...	10/31/2009	$500.00
Protein Kinase Therapeutics in Oncology - Where to Commercialize? By: BioSeeker Group AB This report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. The report extensively analyses 133 identified targets of \| more...	10/29/2009	$3,500.00
CDK Inhibitors Patent Landscape 2009 By: France Innovation Scientifique et Transfer IP Overview presents a patent landscape analysis of the CDK Inhibitor field. Alterations in CDK activity have been associated in the development of viral infections, neurodegenerative dis orders such as Alzheimer’s disease and proliferative \| more... Search inside this report	10/29/2009	$1,645.00
H4-13, Market Access, Pricing, and Reimbursement News in the Third Quarter of 2009 By: Decision Resources Introduction: The third quarter of 2009 saw a heated debate in the United States over healthcare reform, the publication of a report on a European investigation of the pharmaceutical industry, the election of new governments \| more...	10/28/2009	$2,250.00
Antidiabetics in Australia Market Forecast By: Datamonitor Introduction Datamonitor expects the Australian antidiabetics market to reach $416m by 2018. The growth will be driven by the launch of new drug classes, notably the incretin mimetics, and large growth in patient numbers. Although strongest \| more...	10/20/2009	$5,700.00
Biosimilars: Beyond the First Product Wave By: Espicom Healthcare Intelligence With the prospect of high-profile, high-value biosimilar products on the horizon, the sector is poised to realise its full potential - but only if the US can establish a regulatory pathway. This report addresses key \| more... Search inside this report	10/15/2009	$2,460.00

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/22/2009 - 4